[Preliminary study on nasal spray of interferon alpha-2b used for prevention of rubella and measles virus infections].
OBJECTIVE
To evaluate the efficacy of the interferon alpha-2b nasal spray in prevention of rubella and measles virus infections.


METHODS
The properly selected volunteer groups have been divided into interferon alpha-2b experimental and control group. The experimental group received interferon alpha-2b treatment by nasal spray for 2 days before the immunization, then both groups were challenged with rubella and measles attenuated live vaccine respectively through nasal spray. The sera from pre-immunization and 21 and 28 days after immunization were collected to test the IgG antibody titers. The influence on the viral antibody titer reflects the viral preventive effect by interferon alpha-2b.


RESULTS
The antibody titer difference of measles virus between experimental and control group was 1.26 (21 day) and 2.96 (28 day), there were statistically difference between them; the difference of rubella virus was 0.95 (21 day) and 0.37 (28 day), but there were no statistically differences found.


CONCLUSIONS
The preliminary results showed that the interferon alpha-2b can be used as prevention method for measles and rubella viral infections.
Zhao
Jing
J
Beijing Jin Di Ke Institute of Biotechnology, Beijing 100052, China.
Zhu
Feng-cai
FC
Shu
Yue-long
YL
Zhou
Rui
R
Liu
Li-qi
LQ
Zhang
Li-lan
LL
Shi
Zhi-yang
ZY
Tang
Zhen
Z
Lin
Li-zhuo
LZ
Yu
Zhi-ai
ZA
Zhang
Li-ping
LP
Zhang
Bin
B
Hou
Yun-de
YD
D000281:Administration, Intranasal; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008457:Measles / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D008458:Measles Vaccine / Q000276:immunology / Q000627:therapeutic use; D008459:Measles virus / Q000187:drug effects / Q000276:immunology; D011994:Recombinant Proteins; D012409:Rubella / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D012411:Rubella Vaccine / Q000276:immunology / Q000627:therapeutic use; D012412:Rubella virus / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods*; D014613:Vaccines, Attenuated / Q000276:immunology / Q000627:therapeutic use; D055815:Young Adult
D000914:Antibodies, Viral; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008458:Measles Vaccine; D011994:Recombinant Proteins; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated